P. Fenaux
Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
International scoring system for evaluating prognosis in myelodysplastic syndromes.
- P. Greenberg, C. Cox, +12 authors J. Bennett
- Medicine
- Blood
- 15 March 1997
Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses. To attempt to… Expand
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.
- H. Döhner, E. Estey, +16 authors C. Bloomfield
- Medicine
- Blood
- 21 January 2010
In 2003, an international working group last reported on recommendations for diagnosis, response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that time, considerable… Expand
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
- H. Döhner, E. Estey, +19 authors C. Bloomfield
- Medicine
- Blood
- 26 January 2017
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians… Expand
Revised international prognostic scoring system for myelodysplastic syndromes.
- P. Greenberg, H. Tuechler, +31 authors D. Haase
- Medicine
- Blood
- 20 September 2012
The International Prognostic Scoring System (IPSS) is an important standard for assessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS… Expand
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
- P. Fenaux, G. Mufti, +16 authors L. Silverman
- Medicine
- The Lancet. Oncology
- 1 March 2009
BACKGROUND
Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival… Expand
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
- M. Sanz, D. Grimwade, +9 authors F. Lococo
- Medicine
- Blood
- 23 September 2008
The introduction of all-trans retinoic acid (ATRA) and, more recently, arsenic trioxide (ATO) into the therapy of acute promyelocytic leukemia (APL) has revolutionized the management and outcome of… Expand
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
- P. Fenaux, G. Mufti, +13 authors L. Silverman
- Medicine
- Journal of clinical oncology : official journal…
- 1 February 2010
PURPOSE
In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk… Expand
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
- J. Kiladjian, B. Cassinat, +7 authors P. Fenaux
- Medicine
- Blood
- 15 October 2008
Interferon-alpha (IFN-alpha) is a nonleukemogenic treatment of polycythemia vera (PV) able to induce cytogenetic remissions. Its use is limited by toxicity, leading to treatment discontinuation in… Expand
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
- A. Renneville, C. Roumier, +4 authors C. Preudhomme
- Biology, Medicine
- Leukemia
- 21 February 2008
Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great variability in clinical course and response to therapy, as well as in the genetic and molecular basis of the… Expand
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
- C. Preudhomme, C. Sagot, +9 authors H. Dombret
- Medicine
- Blood
- 15 October 2002
The transcription factor C/EBPalpha is crucial for differentiation of mature granulocytes. Recently, different CEBPA gene mutations likely to induce differentiation arrest have been described in… Expand